In clinical trials, post hoc analyses of the cardiovascular outcome have shown that both acute and long-term HDL-raising therapies (four major CETP inhibitors) improved glycemic control and decreased the risk of new-onset diabetes [15,99,100,101]. Here, CETP is linked to diabetes mellitus.